(300 WORDS MAX.)Alzeca Biosciences is developing proprietary technologies to transform the diagnosis of Alzheimer's Disease ("AD"). Alzeca has been supported through several rounds of equity investment and grants to its academic partners.The Challenge:The Disease -- Alzheimer's Disease affects over 5.5M Americans and is the 6th leading cause of death. By 2050, the disease will effect 20M Americans while carrying an annual price tag of >$1 Trillion USD. Lack of Effective Diagnostics -- Currently, AD can only be definitively diagnosed post-mortem. Legacy diagnostic techniques rely primarily on subjective, non-specific psychological testing. As a result, AD is often misdiagnosed and mistreated. In addition, accurate selection of patients for AD drug trials and proving efficacy of such drugs is exceedingly difficult. Such limitations have become a primary bottleneck for the 90+ AD drugs under development. Alzeca Solution Early Screening: The build-up of amyloid plaque in the brain is widely accepted to be the first hallmark of AD. Increasing amyloid plaque density precedes, by 10 years or more, the onset of irreversible cognitive decline associated with AD. Therefore, the ability to image and quantitatively measure amyloid plaque density can provide an early warning of AD and an opportunity for early intervention. Alzeca's "ADx" Particle -- Alzeca has developed an advanced imaging agent, "ADx", to selectively bind and image amyloid plaques, ultimately providing precise, quantitative in-vivo measurement of amyloid plaque density. ADx binding to amyloid plaque is imaged with Magnetic Resonance ("MR") imaging scans. MR has the ability to measure plaque density in three-dimensions and therefore provide a powerful tool for both diagnosis and treatment. From a competitive standpoint, ADx, has the potential to be ~65% less expensive than PET-amyloid agents, while being far more precise, safer (no radiation), less susceptible to false positives, and offers 5-10x more access points to patients.